The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population

References

• American Cancer Society. Key statistics for colorectal cancer. 2021. https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html
   Google Scholar
• Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544–573. doi: 10.1002/cncr.24760.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Fedewa SA, Anderson WF, et al. Colorectal cancer incidence patterns in the United States, 1974–2013. J Natl Cancer Inst. 2017;109(8):djw322.
   PubMedGoogle Scholar
• Wender RC. Should routine screening for colorectal cancer start at 45 years of age? Yes: lowering the starting age is a settled issue. Am Fam Physician. 2022;105(2):120–121.
   PubMedGoogle Scholar
• Davidson KW, Barry MJ, Mangione CM, et al. Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA. 2021;325(19):1965–1977. doi: 10.1001/jama.2021.6238.
   PubMed Web of Science ®Google Scholar
• Knudsen AB, Rutter CM, Peterse EFP, et al. Colorectal cancer screening: an updated modeling study for the US preventive services task force. JAMA. 2021;325(19):1998–2011. doi: 10.1001/jama.2021.5746.
   PubMed Web of Science ®Google Scholar
• Liang PS, Shaukat A. Assessing the impact of lowering the colorectal cancer screening age to 45 years. Lancet Gastroenterol Hepatol. 2020;5(6):523–524. doi: 10.1016/S2468-1253(20)30054-6.
   PubMed Web of Science ®Google Scholar
• Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med. 2012;172(7):575–582. doi: 10.1001/archinternmed.2012.332.
   PubMedGoogle Scholar
• Weiser E, Parks PD, Swartz RK, et al. Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening: real-world data from a large cohort of older adults. J Med Screen. 2021;28(1):18–24. doi: 10.1177/0969141320903756.
   PubMed Web of Science ®Google Scholar
• Miller-Wilson LA, Rutten LJF, Van Thomme J, et al. Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening in a large, nationally insured cohort. Int J Colorectal Dis. 2021;36(11):2471–2480. doi: 10.1007/s00384-021-03956-0.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National Health Interview Survey (NHIS) 2021. 2023. Available from: https://www.cdc.gov/nchs/nhis/index.htm
   Google Scholar
• Warren Andersen S, Blot WJ, Lipworth L, et al. Association of race and socioeconomic status with colorectal cancer screening, colorectal cancer risk, and mortality in Southern US adults. JAMA Netw Open. 2019;2(12):e1917995-e. doi: 10.1001/jamanetworkopen.2019.17995.
   Web of Science ®Google Scholar
• Vahdat V, Alagoz O, Chen J, et al. Calibration and validation of colorectal cancer and adenomia incidence and mortality (CRC-AIM) microsimulation model using deep neural networks. Med Decis Making. 2023;43(6):719–736. doi: 10.1177/0272989X231184175.
   PubMed Web of Science ®Google Scholar
• Piscitello A, Saoud L, Fendrick AM, et al. Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model. PLOS One. 2020;15(12):e0244431. doi: 10.1371/journal.pone.0244431.
   PubMed Web of Science ®Google Scholar
• Piscitello A, Saoud L, Matney M, et al. Description and validation of the colorectal cancer and adenoma incidence & mortality (CRC-AIM) microsimulation model. bioRxiv. 2020.
   Google Scholar
• Hathway JM, Miller-Wilson LA, Jensen IS, et al. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives. J Med Econ. 2020;23(6):581–592. doi: 10.1080/13696998.2020.1730123.
   PubMed Web of Science ®Google Scholar
• Consumer Price Index. Medical care services. 2021. https://beta.bls.gov/dataViewer/view/timeseries/CUSR0000SAM2
   Google Scholar
• MedPAC. Report to the congress: medicare payment policy. 2022. https://www.medpac.gov/document/march-2022-report-to-the-congress-medicare-payment-policy/
   Google Scholar
• Fisher DA, Princic N, Miller-Wilson L-A, et al. Healthcare costs of colorectal cancer screening and events following colonoscopy among commercially insured average-risk adults in the United States. Curr Med Res Opin. 2022;38(3):427–434. doi: 10.1080/03007995.2021.2015157.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule. 2022. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/PAMA-Regulations#where_to_find
   Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–128. doi: 10.1093/jnci/djq495.
   PubMed Web of Science ®Google Scholar
• Pyenson B, Scammell C, Broulette J. Costs and repeat rates associated with colonoscopy observed in medical claims for commercial and medicare populations. BMC Health Serv Res. 2014;14(1):92. doi: 10.1186/1472-6963-14-92.
   PubMedGoogle Scholar
• Szende A, Janssen B, Cabases J, editors. Self-reported population health: an international perspective based on EQ-5D. Dordrecht (NL): Springer; 2014.
   Google Scholar
• Goede SL, Rabeneck L, van Ballegooijen M, et al. Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening. PLOS One. 2017;12(3):e0172864. doi: 10.1371/journal.pone.0172864.
   PubMed Web of Science ®Google Scholar
• Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250–281. doi: 10.3322/caac.21457.
   PubMed Web of Science ®Google Scholar
• Shaukat A, Kahi CJ, Burke CA, et al. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol. 2021;116(3):458–479. doi: 10.14309/ajg.0000000000001122.
   PubMed Web of Science ®Google Scholar
• Patel SG, May FP, Anderson JC, et al. Updates on age to start and stop colorectal cancer screening: recommendations from the U.S. multi-society task force on colorectal cancer. Gastroenterology. 2022;162(1):285–299. doi: 10.1053/j.gastro.2021.10.007.
   PubMed Web of Science ®Google Scholar
• Akram A, Juang D, Bustamante R, et al. Replacing the guaiac fecal occult blood test with the fecal immunochemical test increases proportion of individuals screened in a large healthcare setting. Clin Gastroenterol Hepatol. 2017;15(8):1265.e1–1270.e1. doi: 10.1016/j.cgh.2017.01.025.
   Web of Science ®Google Scholar
• Cooper GS, Grimes A, Werner J, et al. Barriers to follow-up colonoscopy after positive FIT or multitarget stool DNA testing. J Am Board Fam Med. 2021;34(1):61–69. doi: 10.3122/jabfm.2021.01.200345.
   PubMed Web of Science ®Google Scholar
• Ladabaum U, Mannalithara A, Meester RGS, et al. Cost-effectiveness and national effects of initiating colorectal cancer screening for average-risk persons at age 45 years instead of 50 years. Gastroenterology. 2019;157(1):137–148. doi: 10.1053/j.gastro.2019.03.023.
   PubMed Web of Science ®Google Scholar
• Fisher DA, Saoud L, Finney Rutten LJ, et al. Lowering the colorectal cancer screening age improves predicted outcomes in a microsimulation model. Curr Med Res Opin. 2021;37(6):1005–1010. doi: 10.1080/03007995.2021.1908244.
   PubMed Web of Science ®Google Scholar
• Peterse EFP, Meester RGS, Siegel RL, et al. The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: microsimulation analysis I to inform the American cancer society colorectal cancer screening guideline. Cancer. 2018;124(14):2964–2973. doi: 10.1002/cncr.31543.
   PubMed Web of Science ®Google Scholar
• Abualkhair WH, Zhou M, Ahnen D, et al. Trends in incidence of Early-Onset colorectal cancer in the United States among those approaching screening age. JAMA Netw Open. 2020;3(1):e1920407. doi: 10.1001/jamanetworkopen.2019.20407.
   PubMed Web of Science ®Google Scholar
• Bhatt J, Chen J, Vahdat V, et al. Cost-Effectiveness of mt-sDNA versus mailed FIT outreach for medicare advantage enrollees using the CRC-AIM microsimulation model. J Community Med Public Health. 2022;6:266.
   Google Scholar
• Makaroff KE, Shergill J, Lauzon M, et al. Patient preferences for colorectal cancer screening tests in light of lowering the screening age to 45 years. Clin Gastroenterol Hepatol. 2023;21(2):520–531.e10. doi: 10.1016/j.cgh.2022.07.012.
   PubMed Web of Science ®Google Scholar
• National Colorectal Cancer Roundtable. 80% in every community strategic plan. [cited 2023]. Available from: https://nccrt.org/about/how-we-work/80-in-every-community-strategic-plan/.
   Google Scholar